Joseph C. Wu, M.D., Ph.D. is Director of the Stanford Cardiovascular Institute and Simon H. Stertzer Endowed Professor in Department of Medicine (Cardiology) and Department of Radiology at the Stanford School of Medicine. Dr. Wu received his medical degree from Yale and completed his medicine residency and cardiology fellowship training followed by a PhD (molecular pharmacology) at UCLA. Dr. Wu has received many awards, including National Institutes of Health (NIH) Director’s New Innovator Award (2008), NIH Roadmap Transformative Award (2009), American Heart Association (AHA) Innovative Research Award (2009), Presidential Early Career Award for Scientists and Engineers given out by President Obama (2010), AHA Established Investigator Award (2012), Burroughs Wellcome Foundation Innovation in Regulatory Science Award (2015), and AHA Merit Award (2017). He received the Best Basic Science Manuscript Award in Circulation (2006 & 2014), Best Manuscript Award in Circulation Research (2013 & 2017), and the William Parmley outstanding paper award in JACC (2009 & 2017). He also received the inaugural AHA Joseph A. Vita Award (2015) which is given to an investigator whose body of work published in the last 5 years has had transformative impact on basic, translational, or clinical cardiovascular research. Dr. Wu currently serves on the Scientific Advisory Board for the Keystone Symposia (2014-2020), FDA Cellular, Tissue, and Gene Therapies Advisory Committee (2017-2020), AHA National Board of Directors (2017-2019), and Chair of the AHA National Research Committee (2017-2019).
Title of Abstract
Heart disease is the most significant cause of morbidity and mortality in the industrialized world, accounting for nearly 25% of all deaths in the United States alone. While the use of human induced pluripotent stem cell (iPSCs) in regenerative medicine is a long-term goal, a growing body of studies has shown promising results in the fields of drug discovery, development, and toxicity screening. Specifically, recent technological advancement has enabled the generation of patient-specific and disease-specific human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in vitro. These iPSC-CMs carry all the genetic information from the individuals from whom they are derived. Here I will discuss recent advances in this technology and how it may be used for elucidating mechanisms of rare inherited cardiovascular diseases, for drug discovery, and for precision medicine.
Dr. Wu has published >300 manuscripts. His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic cardiovascular disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop "clinical trial in a dish" concept, and (iv) implement precision cardiovascular medicine for prevention and treatment of patients. His lab uses a combination of genomics, stem cells, cellular & molecular biology, physiological testing, and molecular imaging technologies to better understand molecular and pathophysiological processes. Dr. Wu is an Associate Editor for Circulation Research and Senior Guest Editor for JACC: Cardiovascular Imaging. He is also on the editorial board of Journal Clinical Investigator, Circulation Cardiovascular Imaging, Human Gene Therapy, Molecular Therapy, Stem Cell Research, Journal of Nuclear Cardiology, Physiological Genomics, Scientific Report, and Nature Review Cardiology. His clinical activities involve adult congenital heart disease and cardiovascular imaging.